Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Molecular Partners AG - American Depositary Shares (NQ:MOLN)

4.210 -0.040 (-0.94%)
Streaming Delayed Price Updated: 2:47 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Molecular Partners AG - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2023
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
From Molecular Partners
Via GlobeNewswire
News headline image
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
Via MarketBeat
Topics Initial Public Offering
News headline image
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
- Company will also host a reception with Key Opinion Leaders in New Orleans - 
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
From Molecular Partners
Via GlobeNewswire
News headline image
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Planned Departure of Chief Financial Officer
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners AG (NASDAQ:MOLN) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 10/26/2022 -- An investigation was announced for current long-term investors in shares of Molecular Partners AG (NASDAQ:MOLN) concerning potential breaches of fiduciary... 
Via SBWire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million. 
Via Benzinga
News headline image
NASDAQ:MOLN Investor Notice: Deadline Coming Up on September 12, 2022 in Lawsuit Against Molecular Partners AG ↗
San Diego, CA -- (SBWIRE) -- 09/12/2022 -- A deadline is coming up on September 12, 2022 in the lawsuit filed for certain investors of Molecular Partners AG (NASDAQ:MOLN). 
Via SBWire
News headline image
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
FINAL INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Molecular Partners AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
MOLN DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Molecular Partners AG Investors With Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - MOLN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
News headline image
MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.